

## Celleron Therapeutics Co-founder Professor David Kerr awarded Fellowship of ESMO

**Oxford, UK, 22 Sep 2022** – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today that Founder and Chief Medical Officer Prof David Kerr had been made a Fellow of the European Society for Medical Oncology.

The **European Society of Medical Oncology (ESMO)** is committed to offering the best care to people with cancer, through fostering integrated cancer care, supporting oncologists in their professional development, and advocating for sustainable cancer care worldwide.

In 2022 the Society introduced a **Fellow of ESMO (FESMO) Award Programme**, to recognise, thank, and reward ESMO Members who have demonstrated exceptional commitment to the Society. **Prof David Kerr, Oxford, UK** was selected as one of the first recipients of this honour, bestowed at the Paris ESMO Congress.

Professor Kerr CBE MD DSc FRCP FRGCP FACP FESMO FMedSci is a British medical oncologist with over 40 years experience in cancer research. His primary interest is the treatment and management of bowel cancer. He is currently Professor of Cancer Medicine at the University of Oxford, and holds the additional positions of Honorary Consultant Medical Oncologist, Oxford Cancer Centre; Co-Director, Oxford-Sichuan Gastrointestinal Cancer Centre; Honorary Professor of Oncology, Sichuan, Suchow, Xiamen, Zhejiang and 2nd Military Universities, China; and Honorary Professor, Seoul National University, Korea.

In the commercial sector, he has co-founded companies such as Cobra Therapeutics, Oxford Cancer Biomarkers, Celleron Therapeutics, and SynOx Therapeutics.

Professor Kerr was President of ESMO from 2010-2012.

**Professor David Kerr, Chief Medical Officer and Founder of Celleron Therapeutics**, and Professor of Cancer Medicine at Oxford University, commented:

*"I am proud to have made some small contribution towards ESMO's progress to become one of the world's leading professional societies, embracing cancer physicians from almost every nation on the globe. ESMO's guiding philosophy, Good science, Better medicine, Best practice is equally well as applicable to Celleron's approach to developing novel cancer therapeutics".*

## NOTES:

### About Celleron Therapeutics Limited

**Celleron Therapeutics** is a biopharma advancing a clinical and pre-clinical pipeline of precision therapies and vaccines for different cancer indications. The company is a spin-out from Oxford University and located on the Oxford Science Park, UK. Celleron Therapeutics has built a proprietary platform around re-educating the body's immune system to recognise and destroy tumours. Celleron's approach seeks to align the right drug with the right patient enabling a personalised approach to cancer therapy.

Celleron Therapeutics' focus is on those cancers where there is still an unmet need for long-term disease control. It is hoped that not only will patients volunteering for our clinical trials benefit directly, but the results from these studies will ultimately allow the general use of more effective, safer medicines. Our goal is not only to treat cancer, but improve quality of life during therapy by reduction of side effects.

Celleron has global license partnerships with Astra Zeneca and Roche. The company secured investment in 2016 from a consortium of South Korean investors; and in 2020 spun out an affiliate company, SynOx Therapeutics. For more information see [www.cellerontherapeutics.com](http://www.cellerontherapeutics.com)

### About ESMO

Founded in 1975, the **European Society for Medical Oncology (ESMO)** has become the leading professional organisation for medical oncology. It has more than 25,000 members representing oncology professionals from over 160 countries worldwide. ESMO issues Clinical Practice Guidelines that are intended to provide oncology professionals with a set of recommendations for the best standards of cancer care, based on the findings of evidence-based medicine.

In 2015, ESMO published the first version of its Magnitude of Clinical Benefit Scale to grade the magnitude of clinical benefit of cancer therapies incorporating efficacy, long-term survival and side-effects of any anticancer agent into a single score.

ESMO hosts an annual member's Congress, and publishes the journal *Annals of Oncology*. In addition, ESMO produces educational handbooks, and medical oncology training guidelines. The Society provides fellowships for research training for young oncologists, an Exam in Medical Oncology and an accreditation program for institutes providing patients with integrated supportive and palliative care. Through an online professional networking platform ESMO members collaborate, interact and share knowledge on topics of research and clinical practice.